FI951386A0 - Sulfonamidokarbonylpyridin-2-karboxylsyraamider och pyridin-N-oxider därav, förfarande för deras framställning och använding av dem som läkemedel - Google Patents

Sulfonamidokarbonylpyridin-2-karboxylsyraamider och pyridin-N-oxider därav, förfarande för deras framställning och använding av dem som läkemedel

Info

Publication number
FI951386A0
FI951386A0 FI951386A FI951386A FI951386A0 FI 951386 A0 FI951386 A0 FI 951386A0 FI 951386 A FI951386 A FI 951386A FI 951386 A FI951386 A FI 951386A FI 951386 A0 FI951386 A0 FI 951386A0
Authority
FI
Finland
Prior art keywords
alkyl
opt
bond
substd
alkoxy
Prior art date
Application number
FI951386A
Other languages
English (en)
Finnish (fi)
Other versions
FI951386A (sv
Inventor
Klaus Weidmann
Martin Bickel
Volkmar Guenzler-Pukall
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of FI951386A0 publication Critical patent/FI951386A0/sv
Publication of FI951386A publication Critical patent/FI951386A/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
FI951386A 1994-03-25 1995-03-23 Sulfonamidokarbonylpyridin-2-karboxylsyraamider och pyridin-N-oxider därav, förfarande för deras framställning och använding av dem som läkemedel FI951386A (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4410423A DE4410423A1 (de) 1994-03-25 1994-03-25 Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (2)

Publication Number Publication Date
FI951386A0 true FI951386A0 (sv) 1995-03-23
FI951386A FI951386A (sv) 1995-09-26

Family

ID=6513863

Family Applications (1)

Application Number Title Priority Date Filing Date
FI951386A FI951386A (sv) 1994-03-25 1995-03-23 Sulfonamidokarbonylpyridin-2-karboxylsyraamider och pyridin-N-oxider därav, förfarande för deras framställning och använding av dem som läkemedel

Country Status (20)

Country Link
US (1) US5610172A (sv)
EP (1) EP0673931B1 (sv)
JP (1) JPH07278109A (sv)
KR (1) KR950032124A (sv)
CN (1) CN1114312A (sv)
AT (1) ATE156815T1 (sv)
AU (1) AU689199B2 (sv)
CA (1) CA2145476A1 (sv)
CZ (1) CZ287768B6 (sv)
DE (2) DE4410423A1 (sv)
DK (1) DK0673931T3 (sv)
ES (1) ES2105798T3 (sv)
FI (1) FI951386A (sv)
GR (1) GR3024860T3 (sv)
HK (1) HK1012338A1 (sv)
HU (1) HUT72059A (sv)
NO (1) NO304308B1 (sv)
NZ (1) NZ270783A (sv)
PL (1) PL180042B1 (sv)
ZA (1) ZA952408B (sv)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191368B1 (en) 1995-09-12 2001-02-20 Tessera, Inc. Flexible, releasable strip leads
EP2295060B1 (en) 2001-12-06 2018-10-31 Fibrogen, Inc. Treatment or prevention of ischemic or hypoxic conditions
CN1602360A (zh) * 2001-12-06 2005-03-30 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
US20040158289A1 (en) * 2002-11-30 2004-08-12 Girouard Steven D. Method and apparatus for cell and electrical therapy of living tissue
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US7840263B2 (en) * 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) * 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7729761B2 (en) * 2004-07-14 2010-06-01 Cardiac Pacemakers, Inc. Method and apparatus for controlled gene or protein delivery
US7828711B2 (en) * 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) * 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
AU2006259352A1 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of HIF 1alfa modulators for treatment of cancer
US7774057B2 (en) 2005-09-06 2010-08-10 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression for cardiac protection
PL2008460T3 (pl) * 2006-03-30 2017-10-31 Lg Electronics Inc Sposób i urządzenie do dekodowania/kodowania sygnału wideo
HUE041300T2 (hu) 2006-06-26 2019-05-28 Akebia Therapeutics Inc Prolilhidroxiláz inhibitorok és alkalmazási eljárások
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
NO2686520T3 (sv) 2011-06-06 2018-03-17
NZ714963A (en) 2013-06-13 2020-07-31 Akebia Therapeutics Inc Compositions and methods for treating anemia
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
NZ773901A (en) 2015-04-01 2024-07-26 Akebia Therapeutics Inc Compositions and methods for treating anemia
AU2019265629B2 (en) 2018-05-09 2024-09-12 Akebia Therapeutics, Inc. Process for preparing 2-((5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino)acetic acid
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
GR3024860T3 (en) 1998-01-30
DE59500488D1 (de) 1997-09-18
US5610172A (en) 1997-03-11
AU689199B2 (en) 1998-03-26
DK0673931T3 (da) 1998-03-16
CZ73395A3 (en) 1995-11-15
HU9500865D0 (en) 1995-05-29
PL180042B1 (en) 2000-12-29
EP0673931A1 (de) 1995-09-27
HUT72059A (en) 1996-03-28
ES2105798T3 (es) 1997-10-16
CA2145476A1 (en) 1995-09-26
ATE156815T1 (de) 1997-08-15
PL307848A1 (en) 1995-10-02
NO951146D0 (no) 1995-03-24
FI951386A (sv) 1995-09-26
CZ287768B6 (en) 2001-01-17
NO951146L (no) 1995-09-26
AU1504295A (en) 1995-10-05
ZA952408B (en) 1995-11-27
NZ270783A (en) 1997-02-24
JPH07278109A (ja) 1995-10-24
NO304308B1 (no) 1998-11-30
HK1012338A1 (en) 1999-07-30
KR950032124A (ko) 1995-12-20
CN1114312A (zh) 1996-01-03
DE4410423A1 (de) 1995-09-28
EP0673931B1 (de) 1997-08-13

Similar Documents

Publication Publication Date Title
FI951386A0 (sv) Sulfonamidokarbonylpyridin-2-karboxylsyraamider och pyridin-N-oxider därav, förfarande för deras framställning och använding av dem som läkemedel
CZ73495A3 (en) Ester amides of sulfonamidocarbonylpyridine-2-carboxylic acids and their pyridine-n-oxides, process of their preparation and their use as a medicament
PL295331A1 (en) Method of obtaining novel derivatives of quinolonocarboxylic acid
ZA903804B (en) A method of potentiating cell-mediated immunity utilizing polyamine derivatives
EP0244201A3 (en) 3-hydroxypyridines
JPH0481594B2 (sv)
HUT72090A (en) Positive inotropic and lusitropic pyrroloquinolinone derivatives, pharmaceutical compositions containing them and process for their production
FR2611721B1 (fr) Nouveaux derives de l'acide glutamique, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
ES8603865A1 (es) Procedimiento para la preparacion de derivados de pirimidn- tioalquilpiridina
PL312240A1 (en) Novel 3-alkoxycarbonyl-thiadiazinones, method of obtaining them and pharmaceutical preparation and method of obtaining same
HUT50469A (en) Process for producing quinolinecarboxylic acids substituted by heterocyclic group
HUT48893A (en) Process for producing new cepheme derivatives
ZA869742B (en) Novel pregnane derivatives,processes for their preparation and pharmaceutical compositions containing same